Abstract:The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 9.2 million confirmed cases and 478,000 deaths (as of June 24th, 2020). The high intensive care unit (ICU) admission rate and mortality of COVID-19 is continuously posing a serious strain on the global health-care system. While most patients present with mild to moderate symptoms, some patients may develop life-threatening sepsis, respiratory failure, acute respiratory distress syndrome (ARDS) and multiple organ failure. However, current antiviral and supportive therapies are not sufficient to prevent or treat the above complications especially in severely ill COVID-19 patients [1]. Thus, it is urgent to find the underlying mechanism dominating such life-threatening complications. It is well recognized that lung damage and multi-organ failure in this subgroup of patients arise due to overwhelming systemic hyper-inflammation. Therefore, promising anti-inflammatory candidate agents targeting diverse mechanisms related to cytokine storm will be therapeutically relevant (Fig. 1 ). Open in a separate window Fig. 1 Potential therapies of COVID-19 by targeting inflammation and cytokine storm. SARS-CoV-2 enters and infects cells by binding to TMPRSS2 and ACE2, subsequently releases virus RNA, one of the PAMPs, and recruits dendritic cells, macrophages and neutrophils. The released type I interferon and pro-inflammatory cytokines and chemokines induce the innate immune response while adaptive immune response is ignited by activating T and B lymphocytes to defend against the virus. Meanwhile, intact viruses or the components can directly activate the NLRP3 inflammasome, leading to IL-1β secretion. In most infections, moderate immune response and antiviral response are capable to combat the infection. Nevertheless, in individuals with immunological dysfunction, persistent hyper-inflammation triggers a cytokine storm, leading to the lung injury and ARDS or eventually swept through the whole body, causing MODS. During the pathological progression, the inhibition of NRLP3, JAK1/2, IL-6, BRD4 and the infusion of IVIG may be beneficial in suppressing the overwhelming inflammation and arrest or reverse the COVID-19 disease. Abbreviations: ACE2, angiotensin converting enzyme 2; ARDS, acute respiratory distress syndrome; IVIG, intravenous immunoglobulin; MODS, multiple organ dysfunction syndrome; NLRP3, Nod-like receptor protein 3; PAMP, pathogen-associated molecular pattern; TMPRSS2, transmembrane serine protease 2.

Glycyrrhetinic acid: A potential drug for the treatment of COVID-19 cytokine storm

Network pharmacology and bioinformatics analysis identified essential genes of Jingulian in the treatment of rheumatoid arthritis and COVID-19

Therapeutic Targeting of Interleukin-6 for the Treatment of COVID-19.

Efficacy and Safety of Glucocorticoids in Treatment of COVID-19: a Retrospective Study.

Glycyrrhizic Acid: A Natural Plant Ingredient As a Drug Candidate to Treat COVID-19

Glycyrrhizic Acid Nanoparticles as Antiviral and Anti-inflammatory Agents for COVID-19 Treatment

Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm

Application Value of Artificial Liver Support System in the Treatment of Cytokine Storm in Patients with COVID-19

Integrated network pharmacology analysis and in vitro validation revealed the underlying mechanism of Xiyanping injection in treating coronavirus disease 2019

Chlorogenic acid, a natural product as potential inhibitor of COVID-19: virtual screening experiment based on network pharmacology and molecular docking

Glycyrrhetinic acid blocks SARS‐CoV‐2 infection by activating the cGAS‐STING signalling pathway

Network pharmacology and molecular docking analysis reveals the mechanism of asiaticoside on COVID-19

Transcriptomic Signatures and Repurposing Drugs for COVID-19 Patients: Findings of Bioinformatics Analyses

Bioinformatic assay reveal the potential mechanism of Guizhi-Shaoyao-Zhimu decoction against rheumatoid arthritis and mild-to-moderate COVID-19

Nebulized glycyrrhizin/enoxolone drug modulates IL-17A in COVID-19 patients: a randomized clinical trial

Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19

Investigation of an aminothiazole-based scaffold as an anti-inflammatory agent: Potential application in the management of cytokine storm in SARS-CoV-19

Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19

Targeting Inflammation and Cytokine Storm in COVID-19

Are Anti-Inflammatory Drugs Effective In Patients With COVID-19 Cytokine Storm: A Review

Drug Repurposing of Anti-Infective Clinical Drugs: Discovery of Two Potential Anti-Cytokine Storm Agents